Table 2.
Pre-enrolment incidence (%) of bovine respiratory disease (BRD) and isolations of causative bacterial and mycoplasmal pathogens at the five trial sites, and in vitro minimum inhibitory concentration (MIC) of gamithromycin of the isolates
| Number of animals | ||||||||
|---|---|---|---|---|---|---|---|---|
| Number of samples positive for pathogens (MIC gamithromycin range [µg/ml]) | ||||||||
| Trial site | Number of animals in airspace | Number (%) with BRD | Sampled (nasal swabs) | Positive for BRD pathogens | Pm | Mh | Hs | Mb |
| France | 97 | 10 (10.3) | 8 | 2 | 0 | 2 (1.0) | 0 | 1 |
| Germany 1 | 93* | 18 (19.4) | 18 | 12 | 5 (0.125-2.0 | 8 (0.5-1.0) | 0 | 4 |
| Germany 2 | 279 | 34 (12.2) | 34 | 15 | 9 (0.25-2.0) | 2 (0.5-2.0) | 0 | 7 |
| Italy 1 | 281 | 34 (12.1) | 34 | 22 | 0 | 2 (1.0) | 0 | 22 |
| Italy 2 | 249 | 22 (9.0) | 22 | 12 | 0 | 12 (not tested) | 0 | 0 |
| Total | 116 | 63 | 14 (0.125-2.0) | 26 (0.5-2.0) | 0 | 34 (>16)† | ||
*
Additional study animals were added to the airspace after nasal swabs were collected
†
MIC range based on one randomly selected isolate per trial site
Hs Histophilus somni, Mb Mycoplasma bovis, Mh Mannheimia haemolytica, Pm Pasteurella multocida